Skip to Main Content

Cancer biology is a wily foe.

For all the recent treatment breakthroughs using drugs that leverage the immune system, tumors still find ways to avoid being killed. The failure Thursday of an AstraZeneca combination immunotherapy in lung cancer is a humbling setback for the field — and a reminder that many questions remain unanswered.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED